LBA2 ETOP-Roche i-TIMES: Immunotherapy timing investigation on lung cancer survival

ESMO Open 2026 Open access

Read full text
Authors: S. Peters, U. Dafni, J. Federer-Gsponer, M. Ballinger, Maximilian Christopeit, G. Dimopoulou, M. Perol, M. Provencio Pulla, M. Reck, E.F. Smit, Z. Tsourti, S. Morris
+1 more R.A. Stahel
DOI: 10.1016/j.esmoop.2026.106958
Cited by: 2

Abstract

The main objective of the i-TIMES study is to investigate the effect of the timing of immune checkpoint inhibitor (ICI) early vs late in the day, on overall survival (OS) for patients (pts) with lung cancer and secondarily in other solid tumors using data from randomized clinical trials (RCTs).

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Heat shock proteins research Lung Cancer Research Studies

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
106958–106958
Publication date
17 March 2026
Language
EN